You’re receiving this email because you have given Maclean's permission to send you promotions from our trusted partners.
Mitsubishi Tanabe Pharma Canada’s commitment to Canadians living with ALS

For the past five years, Mitsubishi Tanabe Pharma Canada (MTP-CA) has been committed to supporting Canadians diagnosed with Amyotrophic Lateral Sclerosis (ALS) and their caregivers. In 2018, MTP-CA introduced the first new treatment for ALS in almost 20 years and has been at the forefront of research and innovation to support the ALS community ever since. “[We’re] focused on areas that we believe will have the greatest impact for patients—both within and beyond medicine,” says Andy Zylak, president of MTP-CA.

On our site, read about what MTP-CA is doing for the future—and the present—of ALS care.

This message was sent by Maclean's on behalf of 
Mitsubishi Tanabe Pharma Canada | mt-pharma-ca.com

Unsubscribe if you do not wish to receive other partner promotions from Maclean's
To view St. Joseph Communications’ privacy policy, please click here
St. Joseph Communications | 15 Benton Rd, Toronto, ON M6M 3G2